FDA-approved GLP-1 medications and medical weight loss programs may be appropriate for some people
This is especially helpful in the UK, where getting NHS testing can sometimes involve a wait
View PT-141 (Bremelanotide)
Retatrutide is an investigational once-weekly injectable triple agonist that simultaneously activates GLP-1, GIP, and glucagon receptors, targeting appetite, glucose metabolism, and energy expenditure through a single agent
The Trump administration also reached deals with Eli Lilly and Novo Nordisk to lower GLP-1 costs for Medicare, Medicaid, and direct-to-consumer purchases through TrumpRx
J Membr Biol 89:18 Lu SC, Ge JL, Kuhlenkamp J, Kaplowitz N (1992) Insulin and glucocorticoid dependence of hepatic gamma-glutamylcysteine synthetase and glutathione synthesis in the rat